US2016151478A1PendingUtilityA1
Novel Flavivirus Antigens
Est. expiryFeb 26, 2022(expired)· nominal 20-yr term from priority
A61P 31/14A61P 37/04C12N 2770/24134C12N 15/86C07K 14/005A61K 2039/57C07K 2319/00A61K 2039/54C07K 2319/02C12N 2770/24171C12N 2770/24122C07K 14/05A61K 2039/5258C12N 7/00C12N 2770/24123A61K 39/12C12N 2750/14143A61K 2039/545A61K 2039/53A61K 39/00Y02A50/30
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
Claims
exact text as granted — not AI-modified1 . A recombinant or synthetic polypeptide comprising an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:139, 141, 142, 143, 144, 145, 146, 148, 236, 237, 343, or 345.
2 . The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one flavivirus.
3 . The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one dengue virus.
4 . The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a mammal against dengue viruses of multiple serotypes.
5 . The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide comprises the full-length amino acid sequence set forth in SEQ ID NO:139, 141, 142, 143, 144, 145, 146, 148, 236, 237, 343, or 345.
6 . A composition comprising at least one recombinant or synthetic polypeptide and an excipient or carrier, wherein said polypeptide comprises an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:139, 141, 142, 143, 144, 145, 146, 148, 236, 237, 343, or 345.
7 . The composition of claim 6 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one flavivirus.
8 . The composition of claim 6 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one dengue virus.
9 . The composition of claim 6 , wherein the recombinant or synthetic polypeptide induces an immune response in a mammal against dengue viruses of multiple serotypes.
10 . The composition of claim 6 , wherein the recombinant or synthetic polypeptide comprises the full-length amino acid sequence set forth in SEQ ID NO: 139, 141, 142, 143, 144, 145, 146, 148, 236, 237, 343, or 345.
11 . A virus-like particle comprising at least one polypeptide, wherein said polypeptide comprises an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:139, 141, 142, 143, 144, 145, 146, 148, 236, 237, 343, or 345.
12 . The virus-like particle of claim 11 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one flavivirus.
13 . The virus-like particle of claim 11 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one dengue virus.
14 . The virus-like particle of claim 11 , wherein the recombinant or synthetic polypeptide induces an immune response in a mammal against dengue viruses of multiple serotypes.
15 . The virus-like particle of claim 11 , wherein the recombinant or synthetic polypeptide comprises the full-length amino acid sequence set forth in SEQ ID NO: 139, 141, 142, 143, 144, 145, 146, 148, 236, 237, 343, or 345.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.